Esparza-López, José <br/><br/>
Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.  [electronic resource] 

 -  Journal of cancer research and clinical oncology  Oct 2013 
 - 1625-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-1335 
<br/><br/><label>Standard No.: </label>10.1007/s00432-013-1476-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibiotics, Antineoplastic--pharmacology<br/>Benzamides--pharmacology<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>I-kappa B Proteins--metabolism<br/>Imatinib Mesylate<br/>Kinetics<br/>NF-KappaB Inhibitor alpha<br/>NF-kappa B--metabolism<br/>Phosphorylation<br/>Piperazines--pharmacology<br/>Protein Binding<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Processing, Post-Translational--drug effects<br/>Proteolysis<br/>Proto-Oncogene Proteins c-abl--antagonists & inhibitors<br/>Pyrimidines--pharmacology<br/>Transcriptional Activation--drug effects